Codetta Biosciences, a Morrisville, NC-based provider of a digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsiPCR) platform, raised $15M in Series A funding.
The round was led by Anzu Partners with participation from Genoa Ventures and VC23 LLC.
The company intends to use the funds to accelerate the development of its multi-omic dsPCR platform and scale up its workforce in R&D, engineering, marketing, and business administration.
Led by TJ Johnson, CEO, Codetta Biosciences is a life sciences company developing a digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsiPCR) platform for multi-omic analysis from a single specimen. Its integrated platform of reagents, hardware, and software enables simultaneous, multi-plexed, and multi-omic analyses of liquid biopsy and isolated DNA, RNA and protein. The technology enables researchers to analyze viral and bacterial targets, mutations, and deletions, as well as gene and protein expression more efficiently than conventional technologies, providing more high-quality data from a single specimen while maintaining a simple sample-to-answer workflow.
FinSMEs
08/04/2022